Your heart has four valves, and like any good set of doors in an old house, they can start getting creaky. The aortic valve - that's the one between your heart's main pumping chamber and the aorta that sends blood to the rest of your body - is particularly prone to calcifying, stiffening, and generally becoming less cooperative as you age. When it narrows enough, we call it aortic stenosis. When it narrows A LOT, we call it severe aortic stenosis and everyone agrees you need to fix it. But what about when it's only sort of narrowed? That's the question at the heart of NCT05149755, also known as the Evolut EXPAND TAVR II Pivotal Trial.
What's TAVR and Why Should You Care?
TAVR stands for Transcatheter Aortic Valve Replacement, and it's one of those medical innovations that sounds too good to be true. Instead of cracking open your chest, stopping your heart, and performing traditional open-heart surgery (fun for the surgeon, less fun for you), doctors thread a new valve up through your blood vessels - usually from an artery in your leg - and deploy it right on top of your old, broken valve. It's like installing a new door without removing the old frame. The old, crusty valve gets smooshed against the walls while the new valve takes over.
TAVR has been around since the early 2000s and has progressively worked its way down the risk ladder. Initially it was for patients too sick for surgery. Then for high-risk patients. Then intermediate-risk. Now, even low-risk patients can get TAVR instead of surgery in many cases. The results have been genuinely impressive - equal or better outcomes with faster recovery times. It's a triumph of cardiac innovation.
But here's the catch: all that evidence? It's for SEVERE aortic stenosis. Your valve has to be significantly narrowed - an aortic valve area of 1.0 cm squared or less - to qualify. Which brings us to the weird limbo of MODERATE aortic stenosis.
The Moderate Dilemma
Imagine you have a valve that's narrower than it should be, but not narrow enough to meet the official "severe" threshold. You're having symptoms - shortness of breath, fatigue, chest discomfort - but your valve area measures 1.3 cm squared. Sorry, says the medical establishment, you don't qualify for intervention. Come back when you're worse.
This is frustrating on multiple levels. First, patients are symptomatic NOW. They're not having fun with their moderate stenosis; they're feeling genuinely crummy. Second, there's this nagging question: if we KNOW the valve is going to get worse (spoiler: most moderate stenosis eventually becomes severe stenosis), why are we waiting? It's like watching a tire slowly go flat and refusing to change it until it's completely dead.
The Evolut EXPAND TAVR II trial is asking exactly this question. Sponsored by Medtronic and led by the team that developed the Evolut TAVR platform, this multicenter, international, prospective, randomized study is enrolling up to 650 patients at around 100 sites across the US, Canada, Japan, Europe, Australia, and New Zealand. It's a big deal - the first randomized clinical trial specifically designed to test TAVR in patients with moderate, symptomatic aortic stenosis.
How the Trial Works
Participants are randomized into one of two groups. The first receives TAVR using the Evolut PRO+ or Evolut FX system plus guideline-directed medical therapy (GDMT). The second receives GDMT alone - meaning they get optimized medical treatment but no valve intervention. Everyone is then followed for up to ten years to see how things shake out.
The primary endpoints are split into safety and efficacy. At 30 days, researchers measure a composite of bad things you don't want: death, stroke, life-threatening bleeding, acute kidney injury, hospitalization due to device problems, or valve dysfunction requiring another intervention. At two years, they look at a composite of death, heart failure events, or the need for aortic valve intervention.
The trial received FDA Investigational Device Exemption (IDE) approval in October 2021 and Japan PMDA Clinical Trial Approval in February 2022. The first patient was enrolled by Dr. Shigeru Saito's team at Shonan Kamakura General Hospital in Japan. Now it's a matter of waiting for enrollment to complete and the data to mature.
What We've Learned From Related Research (Spoiler: It's Complicated)
While we wait for EXPAND TAVR II results, we're not flying completely blind. The TAVR UNLOAD trial, which presented results at TCT 2024 and was published in the Journal of the American College of Cardiology, examined a related question: what about patients with heart failure and moderate aortic stenosis (doi:10.1016/j.jacc.2024.10.070)?
The results were... nuanced. TAVR was safe in these patients. No major disasters. But it didn't significantly improve the primary outcome - a hierarchical composite endpoint at about 23 months of follow-up. Quality of life was better in the TAVR group during the first year, but that advantage faded as patients in the surveillance arm eventually progressed to severe stenosis and got their valves fixed anyway (43% of the control group underwent TAVR at a median of 12 months).
As one commentator put it, there's "no rush to do TAVI in heart failure patients with moderate AS." The current recommendation remains: wait until moderate stenosis becomes severe, then intervene. The TAVR UNLOAD data didn't change that calculus.
But here's what makes EXPAND TAVR II different: it's using the Evolut self-expanding platform specifically, the patient population is defined differently, and the follow-up is much longer (out to ten years). Long-term outcomes matter enormously in valve disease. A treatment might look equivalent at two years but show clear benefits - or harms - at five or ten years.
The Stakes Are High
Aortic stenosis is not a trivial condition. Once patients become symptomatic with severe stenosis, their prognosis without treatment is grim - often worse than many cancers. Moderate stenosis is less immediately dangerous, but it's a ticking clock. Most patients will progress to severe stenosis within a few years.
The hope with early intervention is that you might be able to prevent some of the cardiac remodeling and damage that occurs during those years of waiting. When your aortic valve is narrowed, your heart has to work harder to push blood through. Over time, this can lead to thickening of the heart muscle, heart failure, and other complications that may not fully reverse even after the valve is fixed.
If EXPAND TAVR II shows that early TAVR prevents these downstream problems, it could fundamentally change how we think about aortic stenosis management. Instead of waiting for patients to deteriorate, we'd be intervening before the damage accumulates.
The Counterargument: Why Not Just Wait?
Of course, there are good reasons to be cautious. TAVR valves are prosthetic, meaning they have their own complications. Pacemaker requirement, paravalvular leak, valve thrombosis, and long-term durability questions all factor into the equation. If a patient with moderate stenosis can be managed medically for several years without harm, why expose them to these risks early?
Additionally, TAVR technology keeps improving. A valve placed in 2025 might be inferior to whatever's available in 2030. By waiting for severe stenosis, patients might benefit from future innovations. It's a weird argument - "wait for your disease to worsen so we can treat you with better technology later" - but it has a certain logic.
The Bottom Line
NCT05149755 represents a critical step in answering one of cardiology's pressing questions: should we intervene earlier in the natural history of aortic stenosis? The trial is well-designed, adequately powered, and asking the right questions.
Current guidelines don't support TAVR for moderate stenosis - and they shouldn't, based on existing evidence. But that's exactly why trials like this exist: to generate the evidence needed to either confirm current practice or justify changing it.
For patients sitting in that frustrating middle ground - symptomatic enough to feel lousy, not severe enough to qualify for treatment - the EXPAND TAVR II trial offers hope that the answer might eventually be different. Whether that hope is justified remains to be seen. We'll know more in a few years.
Until then, if your cardiologist tells you to wait until your stenosis is severe, know that there's a global research effort underway trying to figure out if that advice is right.
Disclaimer: This blog post is for informational purposes only and does not constitute medical advice. Treatment decisions for aortic stenosis should be made in consultation with qualified cardiovascular specialists based on individual patient factors. The trial discussed (NCT05149755) is registered at ClinicalTrials.gov and is currently recruiting participants. Images and graphics are for illustrative purposes only and do not depict actual medical devices, procedures, mechanisms, or research findings from the referenced studies.